202 related articles for article (PubMed ID: 32311221)
21. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
22. Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections.
Lu M; Zhang L; Li Y; Wang H; Guo X; Zhou J; Duan L; Si X; Xu Y; Zhang L
Thorac Cancer; 2020 Mar; 11(3):805-809. PubMed ID: 31970940
[TBL] [Abstract][Full Text] [Related]
23. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
[TBL] [Abstract][Full Text] [Related]
24. Incidence and predictors of infections in patients with advanced non-small cell lung cancer treated with checkpoint inhibitor immunotherapies: A monocentric retrospective cohort study.
Bavaro DF; Diella L; Pizzutilo P; Catino A; Signorile F; Pesola F; Belati A; Marech I; Garrisi V; Lamorgese N; Di Gennaro F; Saracino A; Galetta D
Scand J Immunol; 2023 Sep; 98(3):e13303. PubMed ID: 38441223
[TBL] [Abstract][Full Text] [Related]
25. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
[TBL] [Abstract][Full Text] [Related]
26. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
27. Successful Retreatment Using Pembrolizumab for Non-small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report.
Kobayashi K; Nakachi I; Mitsuishi A; Arai D; Sakurai K; Masaki K; Chiyotani A; Takahashi H; Tahara T; Soejima K
Clin Lung Cancer; 2020 Jan; 21(1):e30-e32. PubMed ID: 31699508
[No Abstract] [Full Text] [Related]
28. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
29. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
30. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
31. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM
J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230
[TBL] [Abstract][Full Text] [Related]
32. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
33. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
Cascone T; Weissferdt A; Godoy MCB; William WN; Leung CH; Lin HY; Basu S; Yadav SS; Pataer A; Mitchell KG; Khan MAW; Shi Y; Haymaker C; Solis LM; Parra ER; Kadara H; Wistuba II; Sharma P; Allison JP; Ajami NJ; Wargo JA; Jenq RR; Gibbons DL; Lee JJ; Swisher SG; Vaporciyan AA; Heymach JV; Sepesi B
Nat Commun; 2021 Aug; 12(1):5045. PubMed ID: 34413300
[TBL] [Abstract][Full Text] [Related]
34. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
35. Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy.
Nigro O; Ferrari A; Casanova M; Orbach D; Leruste A; Gatz SA; Frappaz D; Massimino M
Tumori; 2021 Aug; 107(4):276-281. PubMed ID: 33877022
[TBL] [Abstract][Full Text] [Related]
36. [A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
Liu Y; Zhang T; Gao Y; Qu Y; Lu B; Zhang H; Wang Q; Li J; Hu F; Li B
Zhongguo Fei Ai Za Zhi; 2019 Nov; 22(11):687-695. PubMed ID: 31771737
[TBL] [Abstract][Full Text] [Related]
37. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
[TBL] [Abstract][Full Text] [Related]
38. Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient.
Chen M; Zhang L; Zhong W; Zheng K; Ye W; Wang M
Front Immunol; 2021; 12():619147. PubMed ID: 34040602
[TBL] [Abstract][Full Text] [Related]
39. Use of glucocorticoids in the management of immunotherapy-related adverse effects.
Wang H; Zhou J; Guo X; Li Y; Duan L; Si X; Zhang L
Thorac Cancer; 2020 Oct; 11(10):3047-3052. PubMed ID: 32893490
[TBL] [Abstract][Full Text] [Related]
40. Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer.
Shroff GS; Strange CD; Ahuja J; Altan M; Sheshadri A; Unlu E; Truong MT; Vlahos I
Radiographics; 2022; 42(7):1956-1974. PubMed ID: 36240075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
